Immunobiology of Transfusion
输血免疫生物学
基本信息
- 批准号:9360036
- 负责人:
- 金额:$ 237.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-01 至 2022-06-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAlloantigenAlloimmunizationAlpha CellAmericanAnimal ModelAntibodiesB-LymphocytesBackBasic ScienceBiologyBiometryBloodCD4 Positive T LymphocytesCellsCellular biologyClinicalClinical DataCollaborationsCollectionCytokine Network PathwayDataDiseaseDissectionErythrocyte TransfusionErythrocytesFetusGenerationsGoalsGrantHealthcareHelper-Inducer T-LymphocyteHumanHuman VolunteersImmuneImmune responseImmune signalingImmune systemImmunityImmunizationImmunobiologyImmunoglobulin GImmunologic ReceptorsImmunologicsImmunologyInpatientsInvestigationIsoantibodiesLeadMediatingMedicineModelingMolecularMorbidity - disease rateMusNewborn InfantPathway interactionsPatient CarePatientsPatternPeer ReviewPhysiciansPre-Clinical ModelPrincipal InvestigatorProceduresProductionProductivityProgram Research Project GrantsProphylactic treatmentPublicationsPublishingQuality ControlReactionRegulationReportingResearch PersonnelRoleScientistSeriesSickle Cell AnemiaSignal PathwayStandardizationStimulusStructureSystemT-LymphocyteT-Lymphocyte SubsetsTestingToll-like receptorsTrainingTransfusionWorkacute chest syndromebasebench to bedsideclinically relevantcost effectivecytokineepidemiologic dataimmune activationimmune functionimmunoregulationinnovationinsightmortalitymouse modelmultidisciplinarynovelnovel therapeutic interventionoperationpre-clinicalpreventprogramsresponsesuccesstherapy developmenttooltranslational scientist
项目摘要
Project Summary
This is an application of a Program Project Grant (P01) for a coordinated, multi-disciplinary investigation of the
cellular and molecular mechanisms of immune responses to red blood cell (RBC) transfusion. Though often
lifesaving, transfusions can also lead to RBC alloimmunization, whereby anti-RBC alloantibodies can ultimately
result in both Delayed Hemolytic Transfusion Reactions and/or Hemolytic Disease of the Fetus and Newborn,
leading to morbidity and in some cases mortality. In addition, large quantities of human epidemiological data
indicate that alloantigens on RBCs represent a distinct immune stimulus with a pattern of recipient responses
that differs substantially from better studied scenarios of immunization. Currently, our understanding of how
transfused RBCs drive immune responses (or fail to do so) remains limited. Herein we propose an extensive
collaborative program entitled "Immunobiology of Transfusion" aimed at employing innovative and cutting edge
pre-clinical models and immunological tools, combined with human studies, to experimentally determine the
molecular and cellular pathways that regulate RBC alloimmunization. The proposed program consists of four
projects and two cores. The principal investigator and project leaders are all physician-scientists with formal
basic science training in immunology and also with a clinical focus on transfusion medicine. Moreover, while
this is an application for a new program, it builds upon a decade of collaborative work by the applicant
investigators, providing a historical basis for synergistic collaboration. Project 1 will investigate mechanisms
by which antibodies to RBCs regulate alloimmunization as a model to study anti-RhD immune prophylaxis.
Tested hypotheses include cellular mechanisms of anti-RBC immunoregulation, molecular investigations of the
role of IgG subtypes, and FcR biology. Project 2 will focus on investigation of the role of marginal zone B
cells in RBC alloimmunization, studying both human volunteers and patients with sickle cell disease. Project 3
will investigate which innate immune receptors are activated by transfused RBCs and are functionally required
for T cell dependent RBC alloantibody generation with a focus on MyD88-driven cellular responses,
identification of Toll like receptors involved, and cytokine networks. Project 4 will focus on the biology of
follicular helper T cells and specific cytokine circuits, using pre-clinical models and studying patients with sickle
cell disease. There are two supporting cores. Core A (administrative core) will oversee and coordinate the
administrative, scientific, and fiscal operation of the program as well as providing biostatistics support to all
projects. Core B (mouse blood center core) will set up a cost effective, centralized, quality controlled and
standardized blood collection/processing center for generating units of mouse RBCs that will be used by all 4
projects. Collectively, this program will yield fundamental mechanistic and translational insights into how
transfusion leads to RBC alloimmunization, provide a rational basis to develop new therapeutic interventions
and also generate novel understanding of immunology, in general.
项目概要
这是一项计划项目补助金 (P01) 的申请,旨在对以下问题进行协调一致的多学科调查:
对红细胞(RBC)输注的免疫反应的细胞和分子机制。
挽救生命,输血还可以导致红细胞同种免疫,从而抗红细胞同种抗体最终可以
导致胎儿和新生儿的迟发性溶血性输血反应和/或溶血病,
此外,大量的人类流行病学数据也导致发病和某些情况下的死亡。
表明红细胞上的同种异体抗原代表了一种独特的免疫刺激,具有受体反应的模式
这与目前我们对免疫接种研究的更好方案有很大不同。
输注红细胞驱动免疫反应(或未能这样做)仍然有限,在此我们提出广泛的建议。
题为“输血免疫生物学”的合作项目旨在采用创新和尖端技术
临床前模型和免疫学工具,结合人体研究,通过实验确定
调节红细胞同种免疫的分子和细胞途径 拟议的计划由四个部分组成。
项目和两个核心项目的主要研究者和项目负责人都是具有正式资格的医师科学家。
免疫学基础科学培训以及输血医学临床重点。
这是一个新项目的申请,它建立在申请人十年的合作工作之上
项目 1 将调查机制,为协同合作提供历史基础。
红细胞抗体通过调节同种免疫作为研究抗 RhD 免疫预防的模型。
经检验的假设包括抗红细胞免疫调节的细胞机制、
IgG 亚型的作用和 FcR 生物学 项目 2 将重点研究边缘区 B 的作用。
红细胞同种免疫中的细胞,研究人类志愿者和镰状细胞病患者项目 3。
将研究哪些先天免疫受体被输注的红细胞激活并且是功能所需的
用于 T 细胞依赖性红细胞同种抗体生成,重点关注 MyD88 驱动的细胞反应,
项目 4 将重点关注相关 Toll 样受体的生物学。
滤泡辅助 T 细胞和特定细胞因子回路,使用临床前模型并研究镰状细胞病患者
有两个支持核心 A(行政核心)负责监督和协调。
该计划的行政、科学和财政运作,以及向所有人提供生物统计支持
核心B(小鼠血液中心核心)将建立一个成本有效、集中、质量受控的、
标准化血液采集/处理中心,用于生成小鼠红细胞单位,供所有 4 个单位使用
总的来说,该计划将产生关于如何实现的基本机械和转化见解。
输血导致红细胞同种免疫,为开发新的治疗干预措施提供合理基础
总体而言,还可以产生对免疫学的新理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES C. ZIMRING其他文献
JAMES C. ZIMRING的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES C. ZIMRING', 18)}}的其他基金
Basic and Translational Mechanisms of Alloimmunization to RBC Transfusion. Project 1
红细胞输注同种免疫的基本和转化机制。
- 批准号:
10711668 - 财政年份:2023
- 资助金额:
$ 237.4万 - 项目类别:
Basic and Translational Mechanisms of Alloimmunization to RBC Transfusion
红细胞输注同种免疫的基本机制和转化机制
- 批准号:
10711666 - 财政年份:2023
- 资助金额:
$ 237.4万 - 项目类别:
Immunobiology of Alloimmunization by Platelet Transfusion
血小板输注同种免疫的免疫生物学
- 批准号:
10418747 - 财政年份:2019
- 资助金额:
$ 237.4万 - 项目类别:
Immunobiology of Alloimmunization by Platelet Transfusion
血小板输注同种免疫的免疫生物学
- 批准号:
10192810 - 财政年份:2019
- 资助金额:
$ 237.4万 - 项目类别:
Immunobiology of Alloimmunization by Platelet Transfusion
血小板输注同种免疫的免疫生物学
- 批准号:
10192810 - 财政年份:2019
- 资助金额:
$ 237.4万 - 项目类别:
相似国自然基金
抗骨髓瘤的新型同种异体嵌合抗原受体T(CAR T)细胞疗法研发
- 批准号:82270210
- 批准年份:2022
- 资助金额:68 万元
- 项目类别:面上项目
受体tolDC诱导的供体MHC-I抗原特异性Treg诱导同种异体器官移植免疫耐受
- 批准号:81901627
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
TIGIT活化CD155信号促进调节性APC产生诱导异体复合组织移植免疫耐受的机制及应用研究
- 批准号:81901980
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
靶向Her3的人同种异体CAR-T的建立及其对肿瘤的杀伤作用
- 批准号:81802837
- 批准年份:2018
- 资助金额:20.5 万元
- 项目类别:青年科学基金项目
CTLA4通过非经典NF-κB信号通路诱导EC内IDO表达抑制异体复合组织移植排斥反应
- 批准号:81401615
- 批准年份:2014
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Basic and Translational Mechanisms of Alloimmunization to RBC Transfusion. Project 1
红细胞输注同种免疫的基本和转化机制。
- 批准号:
10711668 - 财政年份:2023
- 资助金额:
$ 237.4万 - 项目类别:
Immunobiology of Alloimmunization by Platelet Transfusion
血小板输注同种免疫的免疫生物学
- 批准号:
10418747 - 财政年份:2019
- 资助金额:
$ 237.4万 - 项目类别:
Immunobiology of Alloimmunization by Platelet Transfusion
血小板输注同种免疫的免疫生物学
- 批准号:
10192810 - 财政年份:2019
- 资助金额:
$ 237.4万 - 项目类别:
Regulation of RBC Alloimmunization by Naturally Occurring and Adaptive Antibodies
天然存在和适应性抗体对红细胞同种免疫的调节
- 批准号:
10160944 - 财政年份:2019
- 资助金额:
$ 237.4万 - 项目类别:
Regulation of RBC Alloimmunization by Naturally Occurring and Adaptive Antibodies
天然存在和适应性抗体对红细胞同种免疫的调节
- 批准号:
9893151 - 财政年份:2019
- 资助金额:
$ 237.4万 - 项目类别: